A phase 3 trial found that adding Imdelltra to Imfinzi maintenance improved survival in extensive-stage small cell lung cancer, while another drug's application was pulled. Here's what patients should know.
Feature|Articles|September 14, 2026
Top 3 Takeaways From WCLC 2026 That Patients Should Know
Author(s)Spencer Feldman
Fact checked by: CURE staff
WCLC 2026 brought new lung cancer data on HER2-mutant, PD-L1-positive and EGFR exon 20 insertion-positive non-small cell lung cancer. Here's what patients should know about three key studies.
Advertisement
Advertisement
The 2026 World Conference on Lung Cancer, held September 12 through 15 in Seoul, South Korea, brought together lung cancer specialists from around the world to share new research. Several studies stood out for their potential to change how certain types of non-small cell lung cancer (NSCLC) are treated. Here are three takeaways patients and caregivers should know.
Related to this article
September brought new options for breast, lung, kidney, bile duct, skin and neuroendocrine cancers, plus a brain tumor scan and easier lung cancer treatment.
Ivonescimab outperformed Keytruda, a new myeloma drug lowered progression risk by 60% and more: the biggest phase 3 cancer results of September 2026.
Replacing two cycles of intensive chemotherapy with Blincyto raised four-year event-free survival to 83% from 70.3% in children with high-risk B-cell ALL, with far fewer infections.
In a trial of 2,175 people with early HER2-positive breast cancer, 43.8% had no invasive cancer left after 12 weeks of a lighter regimen, and certain tumor features predicted who was most likely to respond.
A Phase 3 trial of firmonertinib did not meet its main goal in a hard-to-treat lung cancer subtype, though the drug caused fewer serious side effects than chemotherapy.
In a study of more than 250,000 older adults presented at ASTRO 2026, people with depression who started talk therapy within a week of their cancer diagnosis had a 27% lower risk of dying from their cancer. But most people with depression received no mental health treatment at all.
Epkinly plus R-CHOP lowered the risk of disease progression or death by 51% versus R-CHOP alone in patients with newly diagnosed diffuse large B-cell lymphoma.
Advertisement
Advertisement